Accelerate the identification of promising therapies with our patient-derived tumor models and comprehensive assay services.
Early-stage therapeutic development often struggles with inaccurate models that fail to replicate human tumor biology, leading to lower success rates in later stages of drug development.
We provide in vitro, patient-derived cancer models designed to mimic the complexity of human tumors. Combined with robust assays, these translational models deliver patient-specific insights which can help enhance your therapeutics progress through development stages.
Our models are derived from patient tumor cells rather than traditional cell lines, ensuring more reliable drug assessments.
We source tumor biopsies of specific types and subtypes on your behalf, guaranteeing alignment with your therapeutic focus.
Our bioprinting methodologies create precise replicas of the patient tumor, optimized for high-throughput screening.
This enables a highly relevant and efficient platform for your early drug discovery studies.
